Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Surgery, Beppu Hospital, Kyushu University, Beppu, Japan.
Clin Transplant. 2022 Aug;36(8):e14739. doi: 10.1111/ctr.14739. Epub 2022 Jun 12.
Recently, new diagnostic criteria for acute-on-chronic liver failure (ACLF) were established in Japan. However, there is little evidence regarding the feasibility of classifying patients undergoing living-donor liver transplantation (LDLT). The aim was to re-evaluate the impact of these new diagnostic criteria on ACLF and the severity classification of patients undergoing LDLT.
We collected data of 82 recipients who underwent LDLT for liver failure between 1997 and 2020 and reviewed it retrospectively.
Of the 82 patients with liver failure, 31 (37.8%) were diagnosed with ACLF; Grade 0 (n = 6), Grade 1 (n = 7), Grade 2 (n = 9), and Grade 3 (n = 9). There was no substantial difference in overall survival (OS) and the occurrence of postoperative complications between liver failure patients with and without ACLF. The OS after LDLT was significantly different among the four groups of ACLF patients (P = .036). Interestingly, ACLF Grade 3 patients had substantially lower OS compared to other ACLF groups even after LDLT (P = .006; 5-year OS rates, 33.3% vs. 85.9%).
Proper use of the new diagnostic criteria for ACLF in Japan demonstrated that the presence and severity of ACLF, especially the presence of multiple organ failures, leads to morbidity and mortality even in an LDLT setting. Considering that the patients with ACLF Grade 3 do not have the favorable outcomes of LDLT, deceased-donor liver transplantation usage, or LDLT before reaching the severity of Grade 3 may be suitable for further research.
最近,日本制定了急性慢性肝衰竭(ACLF)的新诊断标准。然而,关于将这些标准应用于活体肝移植(LDLT)患者的可行性,证据有限。本研究旨在重新评估这些新诊断标准对 ACLF 及 LDLT 患者严重程度分级的影响。
我们收集了 1997 年至 2020 年期间 82 例因肝衰竭接受 LDLT 的患者的数据,并进行回顾性分析。
在 82 例肝衰竭患者中,31 例(37.8%)被诊断为 ACLF;0 级(n=6)、1 级(n=7)、2 级(n=9)和 3 级(n=9)。有和无 ACLF 的肝衰竭患者的总生存率(OS)和术后并发症发生率无显著差异。4 组 ACLF 患者的 LDLT 后 OS 存在显著差异(P=0.036)。有趣的是,即使在 LDLT 后,ACLF 3 级患者的 OS 也显著低于其他 ACLF 组(P=0.006;5 年 OS 率,33.3%比 85.9%)。
日本 ACLF 的新诊断标准的合理应用表明,ACLF 的存在和严重程度,尤其是多个器官衰竭的存在,即使在 LDLT 环境中也会导致发病率和死亡率。考虑到 ACLF 3 级患者没有 LDLT 的良好结果,使用死体供肝或在 ACLF 严重程度达到 3 级之前进行 LDLT 可能是进一步研究的合适选择。